Relation Therapeutics

Relation Therapeutics is an AI-driven biopharmaceutical company building a biology-first, lab-and-computation “loop” to identify and validate therapeutic targets from human, high-resolution cellular data. The company’s platform is described as integrating (1) multi-modal patient data (including human genetics and proprietary omics from patient tissue), (2) perturbational omics and translational cellular models to test causal roles of genes in disease-relevant cell states, and (3) an AI/ML layer that includes generative/large language models and graph neural networks, with compute capacity supported via a partnership with NVIDIA. Relation reports an emphasis on improving confidence in what biology to prosecute and using that confidence to prioritize experiments, refine target hypotheses, and progress programs toward clinical value inflection points; its pipeline materials emphasize osteoporosis first, with additional therapeutic areas spanning immunology, metabolic disease, bone disease, and other stated focus areas. Strategic positioning in 2026 includes a large expanded strategic research collaboration with GSK focused on generating high-scale human cellular perturbation datasets and deploying them into Relation’s models, including its cellular biology foundation model MORGAN. Relation says MORGAN is designed to predict how human cells respond to genetic and pharmacological interventions across disease contexts, using petascale multi-omic perturbation datasets generated via automated, high-throughput cellular perturbation experiments intended to support foundation-model training.